Pfizer's upcoming second-quarter earnings report may show a slight miss on profit, even as total revenue holds steady, according to a new forecast from RBC Capital Markets. The investment bank expects the pharmaceutical giant to report earnings per share (EPS) of $0.66, a penny or two below the Wall Street consensus of $0.68.
RBC sees quarterly sales landing near $14.43 billion, roughly in line with analyst expectations. But the mix of what Pfizer is selling matters more than the top-line number. The bank points to cooling demand for Pfizer's COVID-19 products—the vaccine Comirnaty and the antiviral pill Paxlovid—as the main reason for the expected profit shortfall.
Why Profit Is Under Pressure
Comirnaty and Paxlovid were blockbuster moneymakers during the pandemic, generating tens of billions in revenue and carrying high profit margins. As the public health emergency fades and governments shift from bulk purchases to routine seasonal sales, revenue from these products has fallen sharply. Lower-margin products now make up a larger share of Pfizer's sales, dragging down overall profitability.
RBC's estimate suggests that even if total revenue meets expectations, the earnings per share could come up short because of this shift. For everyday investors, this highlights a key risk: a company's profit can miss even when sales look fine, if the product mix changes toward lower-margin items.
Pfizer has been working to offset the decline in COVID-19 revenue through acquisitions and pipeline development. The company completed its $43 billion purchase of Seagen, a cancer drug specialist, in late 2023, and has been investing in new treatments for respiratory syncytial virus (RSV) and other areas. But those efforts take time to bear fruit.
What It Means for Investors
For investors holding Pfizer shares, the upcoming earnings report is a key test of how the company is managing the post-pandemic transition. The stock has been under pressure as COVID-19 product sales declined, and a profit miss could add to that headwind.
However, it's important to keep the numbers in perspective. A miss of $0.02 per share is small, and RBC's forecast is just one analyst's view. The actual results could land anywhere around that range. Investors should watch for management's commentary on the pace of the Seagen integration, the outlook for non-COVID products, and any updates on the company's cost-cutting plans.
Pfizer's situation is not unique. Many companies that benefited from pandemic-era demand are now facing a normalization of sales and profits. For example, PepsiCo recently reported a Q2 beat that failed to convince UBS due to underlying sales and margin concerns, showing how even strong top-line results can mask profit pressures.
Similarly, UBS has forecast a Chipotle sales rebound in the second half despite a near-term margin squeeze, underscoring that margin dynamics are a key focus across sectors right now.
Broader Market Context
The broader market has been volatile, with US equity funds seeing $25 billion in inflows as AI optimism returns. But healthcare stocks have been more mixed, as investors weigh the impact of patent expirations, drug pricing policy, and the post-pandemic demand shift.
Pfizer reports second-quarter earnings on July 30. The company's results will be closely watched not just for the numbers, but for what they signal about the sustainability of its earnings power in a world where COVID-19 is no longer a growth driver.
For everyday investors, the key takeaway is that earnings per share can be more revealing than revenue alone. A company can hit its sales target but still disappoint on profit if the mix of what it sells changes. That's exactly the dynamic RBC is flagging for Pfizer this quarter.
